FDA Approves Dupixent for Chronic Spontaneous Urticaria

FDA Approves Dupixent for Chronic Spontaneous Urticaria

WEDNESDAY, April 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.

Sanofi-Regeneron’s Dupixent gets FDA’s nod for skin condition

(Reuters) -The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron’s blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday. The agency’s green light is a victory for the companies, as the FDA had declined to approve the drug for the skin condition in 2023 and had sought more efficacy data. Dupixent is now cleared with allergy medication for patients aged 12 years and older w…

FDA Approves New Option for Chronic Hives

(MedPage Today) -- The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new targeted drug for the inflammatory skin disease in over a decade, drugmakers Regeneron and Sanofi announced...

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales potential compared to other emerging medicines for the condition.

Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade

The U.S. Food and Drug Administration (FDA) approved Sanofi’s dupilumab (Dupixent) for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 and older … Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade Read More » The post Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade first appeared on GeneOnline News. The post Dupixent Makes History with FDA Approval a…

Companies claim that they expect the population of ECU patients eligible for Dupixent to exceed 300,000 in the United States